Stock comparison
Bio-Rad Laboratories
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BIO
Bio-Rad Laboratories
Market cap
$7.78B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BIO | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 43D | 65C | GMAB |
| Benjamin Graham | 48D | 64C | GMAB |
| Philip Fisher | 30F | 48D | GMAB |
| Peter Lynch | 10F | 25F | GMAB |
| Joel Greenblatt | 42D | 76B | GMAB |
| Charlie Munger | 34F | 68C | GMAB |
| Terry Smith | 26F | 71C | GMAB |
Side-by-side metrics
| Metric | BIO | GMAB |
|---|---|---|
| Market cap | $7.78B | $16.5B |
| P/E (TTM) | 39.5x | 6.2x |
| EV/EBIT | 28.0x | 12.0x |
| ROIC (TTM) | 1.95% | 43.78% |
| Gross margin | 51.87% | 93.88% |
| Net margin | 6.52% | 18.23% |
| Revenue CAGR 5y | -3.04% | -18.45% |
| EPS CAGR 5y | -33.51% | -23.48% |
| Debt / Equity | 0.2x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BIO leads on
- Revenue CAGR 5y-3.04%vs -18.45%+84%
GMAB leads on
- ROIC (TTM)43.78%vs 1.95%+96%
- P/E (TTM)6.2xvs 39.5x+84%
- Net margin18.23%vs 6.52%+64%
- Debt / Equity0.1xvs 0.2x+63%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.